S. Zefkili

On‐axis and off‐axis primary dose component in high energy photon beams

The depth dose of the primary dose component, on axis and off axis of six different x-ray beams, has been determined from transmission measurements in narrow beam geometry with and without flattening filter using a Perspex column of a cross section large enough to ensure electronic equilibrium. In order to derive the primary photon fluence, a correction for the scatter from the column has been applied according to the following method: A number of spectra taken from the literature have been used for computing a scatter coefficient Sc at different depths by convolution of dose spread arrays. Using the relationship between Sc and the single attenuation coefficient mu i to represent each entire spectrum, it has been possible to correct the experimental transmission curves iteratively, until the corresponding values of mu were stabilized and representative of the primary. The measured attenuation coefficients were found to have a linear increase as a function of the distance from the central axis for all the energies and types of linear accelerators. For the same nominal energy, this increase is different from one accelerator to another. The same phenomenon was observed for the attenuation coefficients obtained without the flattening filter in the same experimental conditions. The results are tentatively interpreted considering the angular variation of bremsstrahlung energy spectra with and without a flattening filter as calculated by a Monte Carlo method and they are consistent and useful to take accurately into account the softening of the beam as the off-axis distance increases.

Dose calculation and verification of intensity modulation generated by dynamic multileaf collimators.

While the development of inverse planning tools for optimizing dose distributions has come to a level of maturity, intensity modulation has not yet been widely implemented in clinical use because of problems related to its practical delivery and a lack of verification tools and quality assurance (QA) procedures. One of the prerequisites is a dose calculation algorithm that achieves good accuracy. The purpose of this work was twofold. A primary-scatter separation dose model has been extended to account for intensity modulation generated by a dynamic multileaf collimator (MLC). Then the calculation procedures have been tested by comparison with carefully carried out experiments. Intensity modulation is being accounted for by means of a 2D (two-dimensional) matrix of correction factors that modifies the spatial fluence distribution, incident to the patient. The dose calculation for the corresponding open field is then affected by those correction factors. They are used in order to weight separately the primary and the scatter component of the dose at a given point. In order to verify that the calculated dose distributions are in good agreement with measurements on our machine, we have designed a set of test intensity distributions and performed measurements with 6 and 20 MV photons on a Varian Clinac 2300C/D linear accelerator equipped with a 40 leaf pair dynamic MLC. Comparison between calculated and measured dose distributions for a number of representative cases shows, in general, good agreement (within 3% of the normalization in low dose gradient regions and within 3 mm distance-to-dose in high dose gradient regions). For absolute dose calculations (monitor unit calculations), comparison between calculation and measurement reveals good agreement (within 2%) for all tested cases (with the condition that the prescription point is not located on a high dose gradient region).

The `equivalent wedge' implementation of the Varian Enhanced Dynamic Wedge (EDW) into a treatment planning system

The purpose of this work was to establish procedures for the implementation of the Varian Enhanced Dynamic Wedge into a treatment planning system (TPS), based as much as possible on simple theoretical considerations and already available data. A method is presented for the calculation (rather than measurement) of off-axis relative wedge transmission curves that are required by the TPS for relative dose calculations. We also present a method for absolute dose (monitor unit) calculations, based on the calculation of an effective wedge factor on the prescription point. A simple formula has been derived for the calculation of the effective wedge factor for the most general case, i.e. an arbitrary effective wedge angle, field size and prescription point. Relative dose calculations have been verified by measurements performed on a Varian Clinac 2300C/D linear accelerator, for 6 MV and 20 MV photon energies. Monitor unit calculations have also been verified experimentally for several cases such as symmetric and asymmetric fields with prescription on the collimator axis or on the geometrical centre of the asymmetric field. The presented technique provides results within 2% for both relative and absolute dose calculations for clinically relevant cases.

Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.

This study evaluated adjuvant helical tomotherapy after extrapleural pneumonectomy ± neo-adjuvant chemotherapy in 24 patients with malignant pleural mesothelioma. Toxicity was judged acceptable despite 2 cases (8%) of suspected grade 5 pneumonitis. With a mean follow-up of 7 months, 5 patients had distant and 2 local and distant failure.

Implant breast reconstruction followed by radiotherapy: Can helical tomotherapy become a standard irradiation treatment?

To evaluate the benefits and limitations of helical tomotherapy (HT) for loco-regional irradiation of patients after a mastectomy and immediate implant-based reconstruction. Ten breast cancer patients with retropectoral implants were randomly selected for this comparative study. Planning target volumes (PTVs) 1 (the volume between the skin and the implant, plus margin) and 2 (supraclavicular, infraclavicular, and internal mammary nodes, plus margin) were 50 Gy in 25 fractions using a standard technique and HT. The extracted dosimetric data were compared using a 2-tailed Wilcoxon matched-pair signed-rank test. Doses for PTV1 and PTV2 were significantly higher with HT (V95 of 98.91 and 97.91%, respectively) compared with the standard technique (77.46 and 72.91%, respectively). Similarly, the indexes of homogeneity were significantly greater with HT (p = 0.002). HT reduced ipsilateral lung volume that received ≥20 Gy (16.7 vs. 35%), and bilateral lungs (p = 0.01) and neighboring organs received doses that remained well below tolerance levels. The heart volume, which received 25 Gy, was negligible with both techniques. HT can achieve full target coverage while decreasing high doses to the heart and ipsilateral lung. However, the low doses to normal tissue volumes need to be reduced in future studies.

Analysis of the penumbra enlargement in lung versus the Quality Index of photon beams: A methodology to check the dose calculation algorithm

It is well known that considerable underdosage can occur at the edges of a tumor inside the lung because of the degradation of penumbra due to lack of lateral electronic equilibrium. Although present even at smaller energies, this phenomenon is more pronounced for higher energies. Apart from Monte Carlo calculation, most of the existing Treatment Planning Systems (TPSs) cannot deal at all, or with acceptable accuracy, with this effect. A methodology has been developed for assessing the dose calculation algorithms in the lung region where lateral electronic disequilibrium exists, based on the Quality Index (QI) of the incident beam. A phantom, consisting of layers of polystyrene and lung material, has been irradiated using photon beams of 4, 6, 15, and 20 MV. The cross-plane profiles of each beam for 5x5, 10x10, and 25x10 fields have been measured at the middle of the phantom with the use of films. The penumbra (20%-80%) and fringe (50%-90%) enlargement was measured and the ratio of the widths for the lung to that of polystyrene was defined as the Correction Factor (CF). Monte Carlo calculations in the two phantoms have also been performed for energies of 6, 15, and 20 MV. Five commercial TPSs algorithms were tested for their ability to predict the penumbra and fringe enlargement. A linear relationship has been found between the QI of the beams and the CF of the penumbra and fringe enlargement for all the examined fields. Monte Carlo calculations agree very well (less than 1% difference) with the film measurements. The CF values range between 1.1 for 4 MV (QI 0.620) and 2.28 for 20 MV (QI 0.794). Three of the tested TPSs algorithms could not predict any enlargement at all for all energies and all fields and two of them could predict the penumbra enlargement to some extent. The proposed methodology can help any user or developer to check the accuracy of its algorithm for lung cases, based on a simple phantom geometry and the QI of the incident beam. This check is very important especially when higher energies are used, as the inaccuracies in existing algorithms can lead to an incorrect choice of energy for lung treatment and consequently to a failure in tumor control.

Management of advanced non-melanoma skin cancers using helical tomotherapy.

Helical tomotherapy (HT) is a relatively new method of radiotherapy, the main advantages of which are an increase of irradiation dose on the target tumour volume and best protection of adjacent organs at risk.

Cancers des voies aérodigestives supérieures : bénéfices cliniques de la radiothérapie conformationnelle et de la modulation d'intensité

The conformal radiotherapy approach, three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT), is based on modern imaging modalities, efficient 3D treatment planning systems, sophisticated immobilization systems and rigorous quality assurance and treatment verification. The central objective of conformal radiotherapy is to ensure a high dose distribution tailored to the limits of the target volume while reducing exposure of normal tissues. These techniques would then allow further tumor dose escalation. Head-and-neck tumors are some of the most attractive localizations to test conformal radiotherapy. They combine ballistic difficulties due to particularly complex shapes (nasopharynx, ethmoid) and problems due to the number and low tolerance of neighbouring organs like parotids, eyes, brainstem and spinal cord. The therapeutic irradiation of head-and-neck tumors thus remains a challenge for the radiation oncologist. Conformal radiotherapy does have a significant potential for improving local control and reducing toxicity when compared to standard radiotherapy. However, in the absence of prospective randomized trials, it is somewhat difficult at present to evaluate the real benefits drawn from 3DCRT and IMRT. The published clinical reports on the use of conformal radiotherapy are essentially dealing with dosimetric comparisons on relatively small numbers of patients. Recently, a few publications have emphasized the clinical experience of several precursor teams with a suitable follow-up. This paper describes the current state-of-the-art of 3DCRT and IMRT in order to evaluate the impact of these techniques on head-and-neck cancers irradiation.

Solitary plasmocytoma: improvement in critical organs sparing by means of helical tomotherapy

Purpose:  Helical tomotherapy (HT) was assessed in two patients with paramedullar solitary bone plasmocytoma. We compared doses delivered to critical organs, according HT plan or tridimensional conformal plan.

Potential of Helical Tomotherapy for Sparing Critical Organs in a Patient with AIDS Who Was Treated for Hodgkin Lymphoma

To the Editor—In a recently published article, Hirsch et al. [1] reviewed HIV drug resistance assays used in clinical practice and described a “virtual phenotype” that correlates genotypic data on the plasma HIV-1 RNA of a candidate gene with a large database of paired phenotypes and genotypes. Although the authors cite other bioinformatics systems that generate a calculated fold change (FC), our comments are specific to the Virco Type HIV-1. Hirsch et al. [1] state that virtual phenotype resistance interpretations are limited by a methodology that relies on matches that are based on preselected codons and not on the entire nucleotide sequence and that the “predictive power depends on the number of matched datasets available” [1, p. 274], with high variation for newer drugs with smaller datasets. We would like to note that the matching system used to calculate the FC in their article is no longer the methodology used by the Virco assay. Since July 2006, Virco’s bioinformatics engine has been used to calculate the FC for a given sample by the following method [2]. First, linear regression modeling is performed periodically to analyze the relationship between genotype and phenotype in the Virco correlative database, which to date, has 153,000 samples with paired genotypic and phenotypic data. Significant mutations and mutation pairs that affect phenotypic susceptibility to each drug are identified, and their negative or positive impact on the FC is quantified by a resistance weight factor. Second, all of the mutations in a sample genotype are compared on a drug-by-drug basis to the current list of resistance weight factors for the drug. An FC score is then generated by calculating the sum of the values for all resistance weight factors identified in the sample genotype. This methodology is unlike the first generation of the virtual phenotype, which sought to identify matches to viruses with very similar mutational profiles. With the current linear modeling engine, accurate FC values can be reported regardless of whether there are viruses with similar mutational profiles in the database.